Centre National De La Recherche Scientifique

Pasteur Sanofi Diagnostics

Institut Pasteur

UniversitÉde Strasbourg

Immupharma France Sa

Institut National De La Sante Et De La Recherche Medicale

Université Paris—sud

Biomerieux Sa

Centre International De Recherche Aux Frontieres De La Chimie

Cnrs

Sylviane Muller

Jean-Paul Briand

Gilles Guichard

Marc Van Regenmortel

Bernard Krust

Ara G Hovanessian

Robert H Zimmer

Elias Said

Serge Plaue

Josette Svab

Fanny Sylvie Michele Monneaux

Marcel Hibert

Dominique Bonnet

Jean-Luc Galzi

Robert Zimmer

Alberto Bianco

Sylvie Victorine Lucienne Fournel

Yves Frere

Nelly Frossard

Louis Danicher

Christophe Guignabert

Olivier Busnel

Samira Barakat

Jean-Christophe Weber

Marc Van Reganmortel

Frédéric Simonin

Johan Félicien Heobeke

Gilles François Roger Guichard

Anne Wawrezinieck

Michèle Floc'h Baudy

Jean Gerard Guillet

Fanny Monneaux

Ara Hovanessian

Elias c/o Mr Said Nicolas Said

A subject of the present invention is a compound having the general formula (I):  Another subject of the invention is the compound as defined above for use as a medicament, in particular for preventing and/or treating inflammation and inflammatory diseases, immune and auto-immune diseases, pain related diseases, genetic diseases and/or cancer.

Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines

The present invention relates to a peptide, or a salt thereof, comprising or consisting of the amino acid sequence IHMVYSKRSGKPRGYAFIEY, comprising one or more post-translational modifications, for the treatment, prevention or amelioration of a hyper autophagy-related autoimmune disease or disorder.

Methods of treating chronic inflammatory diseases

The present invention relates to a peptide, or a salt thereof, comprising or consisting of the amino acid sequence IHMVYSKRSGKPRGYAFIEY, comprising one or more post-translational modifications.

Modified peptides and their use for treating autoimmune diseases

The present invention relates to nanoparticles containing a P140 peptide and to carriers, with or without dispersant, containing the nanoparticles. The present invention also relates to pharmaceutical and therapeutic uses of the nanoparticles, in particular for the treatment of systemic lupus erythematosus.

Nanoparticles containing a peptide, vectors containing said nanoparticles, and pharmaceutical uses of said nanoparticles and vectors

The object of the present invention is analogues of peptides or parent proteins, these peptide analogues, comprising at least one aza-&#x3b2;aminoacyl residue, and also their uses in pharmaceutical compositions or for the diagnosis of pathologies wherein the aforesaid peptides or parent proteins are involved.

Peptide analogues comprising at least one type of aminoacylaza-$g(b)&#x3c;sp&#x3e;3&#x3c;/sp&#x3e;and the use thereof, in particular for therapy

Derivatives of the peptide corresponding to the sequence RIHMVYSKRSGKPRGYAFIEY (SEQ ID NO: 1), pharmaceutical compositions, and methods of use thereof are provided.

Phosphorylated derivatives of a U1-70K peptide and their use in the treatment of autoimmune pathologies

The present invention relates to peptides, referred to as CBD-1, CBD-2, CBM-1/TH-1, CBM-1/TH-2, CBM-2/TH-1, CBM-2/TH-2 and C-20 peptides, which are antigenic and elicit a protective immune response against HIV infection. Compositions, pharmaceutical compositions and vaccines comprising these antigenic peptides are also encompassed by the present invention, as well as neutralizing antibodies which inhibit infection of primary CD4+ T lymphocytes by various HIV isolates. Methods for diagnosis of HIV are also disclosed.

Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV

The invention relates to a multimeric molecule which can imitate a natural multimeric proteinaceous ligand. The invention also relates to a multimeric molecule as defined above which is characterised in that it has the following general formula: A-X, wherein: n is equal to 3, 4, 5 or 6; A denotes a chemical group which is functionalised by at least three amine functions or COOH functions; and X denotes a D, B-D or B(D)-D' group, in which B is a spacer and D and D&#x2032; are peptides or pseudopeptides corresponding to a sequence which is derived from the ligand and selected from residual matter forming the interface with the receptor and which can interact with the receptor.

Multimeric molecules, the preparation method thereof and use of same for the preparation of medicaments

This invention is directed toward methods and kits for the detection of antibodies associated with autoimmune disorders or infectious agents in an individual employing immunoretroid peptides derived from antigens associated with said disorders and agents. These immunoretroid compounds are derived from the following group of peptides: the foot-and-mouth disease virus major antigenic determinant VP1 peptide &lsqb;A&rsqb;, the foot-and-mouth disease virus major antigenic determinant VP1 peptide &lsqb;USA&rsqb;, the influenza virus strain X31 site A peptide, the C-terminal epitope of the histone protein H3 consisting of amino acids 130-135, an internal epitope of the histone protein H3 consisting of amino acids 28-45, an internal epitope of the recombinant 52 kDa autoimmune protein SSA/Ro (Ro52) consisting of amino acids 277-291, an internal epitope of the recombinant 60 kDa autoimmune protein SSA/Ro (Ro60) consisting of amino acids 304-324, the foot-and-mouth disease virus immunodominant loop peptide FP, the foot-and-mouth disease virus immunodominant loop peptide FL, and the foot-and-mouth disease virus immunodominant loop peptide SL. The immunoretroids derived from these peptides are capable of binding to the aforementioned antibodies with equal affinity as compared to the native antigen.

Methods for the detection of antibodies associated with autoimmune disorders and infectious agents employing immunoretroid peptides derived from antigens associated with said disorders and agents

Peptides possessing some of the immunological properties of the peptide of the formula Gly-Gly-Arg-Leu; Lys-Lys-Thr-Glu. Application to the diagnosis of certain autoimmune diseases and to the vaccine.

Synthetic peptides of the conjugate of ubiquitine and H2A histone

Peptides of the SM-D antigen and their use for diagnosis of systemic

Growing community of inventors

Strasbourg, France

Sylviane Muller